Advent and Medicxi lead £11m series-A for Capella
Advent Life Sciences, Medicxi Ventures (Index Venturesт life sciences vehicle) and Osage University Partners have led a ТЃ11m series-A for London-based biotechnology business Capella Bioscience.
The capital injection will finance ongoing development of Capella's therapeutic treatments programme.
Osage University Partners' Bill Harrington will step onto the board of Capella in an observer role as part of the funding round.
Previous funding
In June 2014, Advent and Medicxi helped found Capella with a £1.5m seed round.
Company
Headquartered in London, Capella is a biotech company focused on developing therapeutics based on monoclonal antibodies.
People
Advent Life Sciences – Raj Parekh (general partner).
Capella Bioscence – Steve Holmens (COO).
More on Early-stage
World Fund leads EUR 128m raise for quantum computing group IQM
Series-A2 for Finnish startup focused on combating the climate crisis also backed by the EIB
Gorillas raises circa USD 1bn in Delivery Hero-led Series C
New funding comes just seven months after a Series B, with the company doubling in value
L Catterton et al. in EUR 100m round for SellerX
SellerX has already raised amost EUR 250m in debt and equity in its 12 months since inception
Point72 Ventures leads €20m round for Curb
Food startup was founded in 2020 and will use the funding to invest in technology and its expansion in Stockholm
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds